Get the Stockscreener App
5.03
0.59%
-0.03
After Hours:
5.06
0.03
+0.60%
Elicio Therapeutics Inc stock is traded at $5.03, with a volume of 26,964.
It is down -0.59% in the last 24 hours and up +32.37% over the past month.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.
See More
Previous Close:
$5.06
Open:
$5.08
24h Volume:
26,964
Relative Volume:
0.82
Market Cap:
$54.52M
Revenue:
-
Net Income/Loss:
$-33.82M
P/E Ratio:
-0.1897
EPS:
-26.5174
Net Cash Flow:
$-66.04M
1W Performance:
+1.00%
1M Performance:
+32.37%
6M Performance:
-33.82%
1Y Performance:
-40.47%
1-Day Range:
$4.78
$5.10
1-Week Range:
$4.59
$5.10
52-Week Range:
$2.96
$11.45
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Name
Elicio Therapeutics Inc
Sector
Industry
Phone
(857) 209-0050
Address
451 D STREET, 5TH FLOOR, BOSTON
Elicio Therapeutics Inc Stock (ELTX) Latest News
Elicio Therapeutics reports inducement grants - TipRanks
Elicio Therapeutics Reports Inducement Grants - GlobeNewswire
Elicio Therapeutics Reports Inducement Grants - EIN News
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted - The Bakersfield Californian
Elicio Therapeutics Announces Three Upcoming Presentations - GlobeNewswire
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines - StockTitan
Elicio Therapeutics CFO resigns to pursue new opportunity By Investing.com - Investing.com Australia
Elicio Therapeutics CFO resigns to pursue new opportunity - Investing.com
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Yahoo Finance
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q2 2024 - InvestorPlace
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - BioSpace
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - StockTitan
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates - wallstreet:online
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note - GlobeNewswire
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note - Yahoo Finance
Elicio Therapeutics’ US$40 Million ATM and US$11.5 Million Public Offering - Global Legal Chronicle
Therapeutic Vaccine Industry to Witness Massive Growth - openPR
ASCO 2024Chris Haqq - pharmaphorum
Ratios in Focus: Analyzing Elicio Therapeutics Inc. (ELTX)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday? - MSN
Elicio Therapeutics sets $11.5 million stock offering By Investing.com - Investing.com Australia
Orion Group Holdings inks $30.5M land sale deal By Investing.com - Investing.com
Apple shares target raised, reiterates Outperform on AI potential By Investing.com - Investing.com
Elicio Therapeutics Shares Drop 35% After Public Offering Prices - MarketWatch
Elicio Therapeutics sets $11.5 million stock offering By Investing.com - Investing.com UK
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?Elicio Therapeutics (NASDAQ ... - Benzinga
Elicio Therapeutics Prices of $11.5 Million Underwritten Public Offering - citybiz
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering - GlobeNewswire
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering - StockTitan
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today? - InvestorPlace
Elicio Therapeutics launches public offering of stock and warrants By Investing.com - Investing.com Australia
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday? - Benzinga
Elicio reports promising early results in cancer vaccine trial By Investing.com - Investing.com Australia
Elicio reports promising early results in cancer vaccine trial By Investing.com - Investing.com
Elicio Therapeutics launches public offering of stock and warrants By Investing.com - Investing.com India
Elicio Therapeutics launches public offering of stock and warrants - Investing.com
Elicio Therapeutics Shares Slip 28% After Public Offering, Drug Data - MarketWatch
Form 424B5 Elicio Therapeutics, - StreetInsider.com
SEC Form 424B5 filed by Elicio Therapeutics Inc. - Quantisnow
Elicio Therapeutics’ Promising Early Results in Cancer Vaccine Trial - TipRanks
Elicio Therapeutics Announces Proposed Public Offering - ForexTV.com
Elicio Therapeutics shares are trading lower after the company announced preliminary disease-free survival analysis ... - Quantisnow
Elicio Therapeutics Announces Proposed Public Offering - GlobeNewswire
Elicio Therapeutics Announces Proposed Public Offering - GlobeNewswire Inc.
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing ... - The Bakersfield Californian
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a ... - GlobeNewswire
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a ... - Yahoo Finance
Elicio Therapeutics Announces Proposed Public Offering - Yahoo Finance
Elicio Therapeutics Inc Stock (ELTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):